Quick Answer
Oric Pharmaceuticals, Inc. reported Diluted EPS of $1.47 per share (loss) for fiscal year 2025.
Oric Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.47 | +19.7% |
| 2024 | -$1.83 | +6.6% |
| 2023 | -$1.96 | +12.9% |
| 2022 | -$2.25 | -8.7% |
| 2021 | -$2.07 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.33 | +32.7% | +29.8% |
| June 30, 2025 | -$0.47 | -4.4% | -11.9% |
| March 31, 2025 | -$0.42 | -13.5% | +14.3% |
| September 30, 2024 | -$0.49 | -11.4% | -8.9% |
| June 30, 2024 | -$0.45 | +10.0% | -21.6% |
| March 31, 2024 | -$0.37 | +30.2% | +15.9% |
| September 30, 2023 | -$0.44 | +30.2% | +12.0% |
| June 30, 2023 | -$0.50 | +2.0% | +5.7% |
- Oric Pharmaceuticals, Inc. showed an increase of +19.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Oric Pharmaceuticals, Inc.’s diluted eps has grown by 29.0% (from $2.07 per share (loss) to $1.47 per share (loss)).
- The most recent figure is from Oric Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: